Nitrate tolerance as a model of vascular dysfunction: Roles for mitochondrial aldehyde dehydrogenase and mitochondrial oxidative stress

Pharmacological Reports

Volumn 61, Issue 1, 2009, Pages 33-48

  Daiber, Andreas ^a   Oelze, Matthias ^a   Wenzel, Philip ^a   Wickramanayake, Jennifer M Dias ^a   Schuhmacher, Swenja ^a   Jansen, Thomas ^a   Lackner, Karl J ^a   Torzewski, Michael ^a   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Mitochondrial aldehyde dehydrogenase; Mitochondrial oxidative stress; Organic nitrate; Peroxynitrite; Superoxide; Vascular dysfunction

Indexed keywords

ALDEHYDE DEHYDROGENASE; GLYCERYL TRINITRATE; HEME OXYGENASE 1; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; ORGANIC NITRATE; PENTAERYTHRITYL TETRANITRATE; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANTIOXIDANT ACTIVITY; CATALYSIS; CELL INTERACTION; CONFERENCE PAPER; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; LOW DRUG DOSE; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; RISK FACTOR; VASCULAR DISEASE; VASODILATATION;

EID: 66949115572     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70005-2     Document Type: Conference Paper

References (96)

1. Abou-Mohamed G, Johnson JA, Jin L, El-Remessy AB, Do K, Kaesemeyer WH, Caldwell RB, Caldwell RW: Roles of superoxide, peroxynitrite, and protein kinase c in the development of tolerance to nitroglycerin. J Pharmacol Exp Ther, 2004, 308, 289-299.
2. Abrams J: Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol, 1992, 70, 30B-42B.
3. Arnold WP, Mittal CK, Katsuki S, Murad F: Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA, 1977, 74, 3203-3207.
4. Bachschmid M, Schildknecht S, Ullrich V: Redox regulation of vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem Biophys Res Commun, 2005, 338, 536-542.
5. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol Cell Physiol, 1996, 271, C1424-1437.
6. Berkenboom G, Fontaine D, Unger P, Baldassarre S, Preumont N, Fontaine J: Absence of nitrate tolerance after long-term treatment with ramipril: An endothelium-dependent mechanism. J Cardiovasc Pharmacol, 1999, 34, 547-553.
7. Bilska A, Włodek L: Lipoic acid - the drug of the future? Pharmacol Rep, 2005, 57, 570-577.
8. Brandes RP: Triggering mitochondrial radical release: A new function for NADPH oxidases. Hypertension, 2005, 45, 847-848.
9. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res, 2000, 87, 840-844.
10. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D: Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science, 2008, 321, 1493-1495.
11. Chen Z, Stamler JS: Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med, 2006, 16, 259-265.
12. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA, 2002, 99, 8306-8311.
13. Cheng ZJ, Vapaatalo H, Mervaala E: Angiotensin II and vascular inflammation. Med Sci Monit, 2005, 11, RA194-205.
14. Daiber A, Gori T: Vascular tolerance to nitroglycerin in ascorbate deficiency - results are in favor of an important role of oxidative stress in nitrate tolerance. Cardiovasc Res, 2008, 79, 722-723.
15. Daiber A, Münzel T: Oxidative stress, redoxregulation and NO-bioavailability - experimental and clinical aspects (German). Steinkopff Verlag, Darmstadt, 2006.
16. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M et al.: Oxidative stress and mitochondrial aldehyde dehydrogenase activity: A comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol, 2004, 66, 1372-1382.
17. Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, Schildknecht S, Bachschmid M et al.: Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun, 2005, 338, 1865-1874.
18. +/-): A novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol, 2005, 68, 579-588.
19. Daiber A, Ullrich V: Radical chemistry in the organism: nitrogen monoxide, superoxide and peroxynitrite (German). Chemie in unserer Zeit, 2002, 36, 366-375.
20. Daiber A, Wenzel P, Oelze M, Munzel T: New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol, 2008, 97, 12-20.
21. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A et al.: Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation, 2005, 112, 2668-2676.
22. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, Sorrentino S et al.: Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res, 2007, 100, 894-903.
23. Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: Linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res, 2008, 102, 488-496.
24. Dragoni S, Gori T, Lisi M, Di Stolfo G, Pautz A, Kleinert H, Parker JD: Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol, 2007, 27, 1955-1959.
25. Dudek M, Bednarski M, Bilska A, Iciek M, Sokołowska-Jezewicz M, Filipek B, Włodek L: The role of lipoic acid in prevention of nitroglycerin tolerance. Eur J Pharmacol, 2008, 591, 203-210.
26. Dulak J, Deshane J, Jozkowicz A, Agarwal A: Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angiogenesis. Circulation, 2008, 117, 231-241.
27. Esplugues JV, Rocha M, Nunez C, Bosca I, Ibiza S, Herance JR, Ortega A et al.: Complex I dysfunction and tolerance to nitroglycerin: An approach based on mitochondrial-targeted antioxidants. Circ Res, 2006, 99, 1067-1075.
28. Fan Q, Gao F, Zhang L, Christopher TA, Lopez BL, Ma XL: Nitrate tolerance aggravates postischemic myocardial apoptosis and impairs cardiac functional recovery after ischemia. Apoptosis, 2005, 10, 1235-1242.
29. Florczyk UM, Jozkowicz A, Dulak J: Biliverdin reductase: New features of an old enzyme and its potential therapeutic significance. Pharmacol Rep, 2008, 60, 38-48.
30. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation, 2006, 113, 1708-1714.
31. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG et al.: p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res, 1997, 80, 45-51.
32. Fung HL: Biochemical mechanism of nitroglycerin action and tolerance: Is this old mystery solved? Annu Rev Pharmacol Toxicol, 2004, 44, 67-85.
33. Gao J, Xiong Y, Ho YS, Liu X, Chua CC, Xu X, Wang H et al.: Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim Biophys Acta, 2008, 1783, 2020-2029.
34. Gokce N, Keaney JF, Jr., Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA: Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol, 2003, 41, 1769-1775.
35. Gori T, Al-Hesayen A, Jolliffe C, Parker JD: Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol, 2003, 91, 1392-1394.
36. Gori T, Di Stolfo G, Sicuro S, Dragoni S, Lisi M, Forconi S, Parker JD: Nitroglycerin protects the endothelium from ischaemia and reperfusion: Human mechanistic insight. Br J Clin Pharmacol, 2007, 64, 145-150.
37. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation, 2003, 108, 1912-1916.
38. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part II: Animal and human studies. Circulation, 2003, 108, 2034-2040.
39. Hausenloy D, Wynne A, Duchen M, Yellon D: Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation, 2004, 109, 1714-1717.
40. Heistad DD: Oxidative stress and vascular disease: 2005 Duff lecture. Arterioscler Thromb Vasc Biol, 2006, 26, 689-695.
41. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 2001, 104, 2673-2678.
42. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, Mollnau H et al.: Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol, 2003, 42, 1826-1834.
43. Hirai N, Kawano H, Yasue H, Shimomura H, Miyamoto S, Soejima H, Kajiwara I et al.: Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina. Circulation, 2003, 108, 1446-1450.
44. Jakschik B, Needleman P: Sulfhydryl reactivity of organic nitrates: Biochemical basis for inhibition of glyceraldehyde-P dehydrogenase and monoamine oxidase. Biochem Biophys Res Commun, 1973, 53, 539-544.
45. Jurt U, Gori T, Ravandi A, Babaei S, Zeman P, Parker JD: Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: A human in vivo study. J Am Coll Cardiol, 2001, 38, 854-859.
46. Klumpp G, Schildknecht S, Nastainczyk W, Ullrich V, Bachschmid M: Prostacyclin in the cardiovascular system: New aspects and open questions. Pharmacol Rep, 2005, 57, Suppl, 120-126.
47. Kurz S, Hink U, Nickenig G, Borthayre AB, Harrison DG, Munzel T: Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation, 1999, 99, 3181-3187.
48. phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension, 2002, 40, 511-515.
49. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG: Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest, 2003, 111, 1201-1209.
50. Lau D, Baldus S: Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther, 2006, 111, 16-26.
51. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. Cardiovasc Res, 2007, 75, 530-535.
52. Longobardi G, Ferrara N, Leosco D, Abete P, Furgi G, Cacciatore F, Corbi G et al.: Angiotensin II-receptor antagonist losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease. Cardiovasc Drugs Ther, 2004, 18, 363-370.
53. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S et al.: Nox1 is involved in angiotensin II-mediated hypertension: A study in Nox1-deficient mice. Circulation, 2005, 112, 2677-2685.
54. Mihm MJ, Coyle CM, Jing L, Bauer JA: Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther, 1999, 291, 194-198.
55. Milone SD, Azevedo ER, Forster C, Parker JD: The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol, 1999, 34, 645-650.
56. Minuz P, Fava C, Lechi A: Lipid peroxidation, isoprostanes and vascular damage. Pharmacol Rep, 2006, 58, Suppl, 57-68.
57. +/- mice. BMC Cardiovasc Disord, 2006, 6, 44.
58. Mülsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, Walter U et al.: Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation, 2001, 103, 2188-2194.
59. Münzel T, Bassenge E: Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation, 1996, 93, 2052-2058.
60. Münzel T, Daiber A, Mülsch A: Explaining the phenomenon of nitrate tolerance. Circ Res, 2005, 97, 618-628.
61. Münzel T, Daiber A, Ullrich V, Mülsch A: Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol, 2005, 25, 1551-1557.
62. Münzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG: Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA, 1995, 92, 5244-5248.
63. Münzel T, Harrison DG: Evidence for a role of oxygen-derived free radicals and protein kinase c in nitrate tolerance. J Mol Med, 1997, 75, 891-900.
64. Münzel T, Heitzer T, Kurz S, Harrison DG, Luhman C, Pape L, Olschewski M, Just H: Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol, 1996, 27, 297-303.
65. Münzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG: Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest, 1996, 98, 1465-1470.
66. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG: Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest, 1995, 95, 187-194.
67. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C: Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale postinfarction studies. Multicenter myocardial ischemia research group. Am Heart J, 1999, 138, 577-585.
68. Needleman P, Hunter FE, Jr.: Effects of organic nitrates on mitochondrial respiration and swelling: Possible correlations with the mechanism of pharmacologic action. Mol Pharmacol, 1966, 2, 134-143.
69. Needleman P, Johnson EM, Jr.: Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther, 1973, 184, 709-715.
70. Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT et al.: Endothelial protection by pentaerithrityl trinitrate: Bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood), 2003, 228, 529-534.
71. Oberle S, Schwartz P, Abate A, Schroder H: The antioxidant defense protein ferritin is a novel and specific target for pentaerithrityl tetranitrate in endothelial cells. Biochem Biophys Res Commun, 1999, 261, 28-34.
72. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987, 327, 524-526.
73. Radomski MW, Palmer RM, Moncada S: The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol, 1987, 92, 639-646.
74. Ren J: Acetaldehyde and alcoholic cardiomyopathy: Lessons from the ADH and ALDH2 transgenic models. Novartis Found Symp, 2007, 285, 69-76; discussion 76-69, 198-199.
75. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, Stubberfield J, Horowitz JD: Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation, 2000, 102, 2810-2815.
76. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101, 1899-1906.
77. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmuller S et al.: Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation, 2002, 105, 1170-1175.
78. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K: Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol, 2005, 46, 63-67.
79. Strassburger M, Bloch W, Sulyok S, Schuller J, Keist AF, Schmidt A, Wenk J et al.: Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic Biol Med, 2005, 38, 1458-1470.
80. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, Ullrich V et al.: Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest, 2004, 113, 482-489.
81. Thomas GR, DiFabio JM, Gori T, Parker JD: Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: Evidence of a free-radical-mediated mechanism. J Am Coll Cardiol, 2007, 49, 1289-1295.
82. Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, Münzel T et al.: Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol, 2007, 27, 748-754.
83. Torzewski M, Ochsenhirt V, Kleschyov AL, Oelze M, Daiber A, Li H, Rossmann H et al.: Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol, 2007, 27, 850-857.
84. Towell J, Garthwaite T, Wang R: Erythrocyte aldehyde dehydrogenase and disulfiram-like side effects of hypoglycemics and antianginals. Alcohol Clin Exp Res, 1985, 9, 438-442.
85. Warnholtz A, Buse J, Wild P, Münzel T: Prognostic value of endothelial dysfunction (German). Kardiologie up2date, 2006, 2, 218-225.
86. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A et al.: Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol, 2002, 40, 1356-1363.
87. Wennmalm A: Endothelial nitric oxide and cardiovascular disease. J Intern Med, 1994, 235, 317-327.
88. Wenzel P, Hink U, Oelze M, Schuppan S, Schaeuble K, Schildknecht S, Ho KK et al.: Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem, 2007, 282, 792-799.
89. -/- mice. Br J Pharmacol, 2007, 150, 526-533.
90. Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JM, Muller J, Schuhmacher S et al.: First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal, 2008, 10, 1435-1447.
91. Wenzel P, Muller J, Zurmeyer S, Schuhmacher S, Schulz E, Oelze M, Pautz A et al.: ALDH-2 deficiency increases cardiovascular oxidative stress - evidence for indirect antioxidative properties. Biochem Biophys Res Commun, 2008, 367, 137-143.
92. Wenzel P, Oelze M, Coldewey M, Hortmann M, Seeling A, Hink U, Mollnau H et al.: Heme oxygenase-1. A novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol, 2007, 27, 1729-1735.
93. Wenzel P, Schuhmacher S, Kienhofer J, Muller J, Hortmann M, Oelze M, Schulz E et al.: MnSOD and ALDH-2 deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc Res, 2008, 80, 280-289.
94. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM: Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation, 1989, 80, 198-205.
95. Xiong Y, Shie FS, Zhang J, Lee CP, Ho YS: The protective role of cellular glutathione peroxidase against trauma-induced mitochondrial dysfunction in the mouse brain. J Stroke Cerebrovasc Dis, 2004, 13, 129-137.
96. Zou MH, Ullrich V: Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett, 1996, 382, 101-104.